Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria

Kaplan, 2013, Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy, J Allergy Clin Immunol, 132, 101, 10.1016/j.jaci.2013.05.013

Eckman, 2008, Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies, J Invest Dermatol, 128, 1956, 10.1038/jid.2008.55

Guttman-Yassky, 2007, The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals, J Eur Acad Dermatol Venereol, 21, 35, 10.1111/j.1468-3083.2006.01852.x

Eckman, 2009, Independent evaluation of a commercial test for “autoimmune” urticaria in normal and chronic urticaria subjects, J Invest Dermatol, 129, 1584, 10.1038/jid.2008.416

Yasnowsky, 2006, Chronic urticaria sera increase basophil CD203c expression, J Allergy Clin Immunol, 117, 1430, 10.1016/j.jaci.2006.02.016

Beck, 2004, Omalizumab-induced reductions in mast cell Fce psilon RI expression and function, J Allergy Clin Immunol, 114, 527, 10.1016/j.jaci.2004.06.032

MacGlashan, 1997, Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody, J Immunol, 158, 1438, 10.4049/jimmunol.158.3.1438

Metz, 2014, Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis, J Dermatol Sci, 7, 57, 10.1016/j.jdermsci.2013.08.011

Altrichter, 2011, IgE mediated autoallergy against thyroid peroxidase—a novel pathomechanism of chronic spontaneous urticaria?, PLoS One, 6, e14794, 10.1371/journal.pone.0014794